Hematology Frontier

Thrombotic diseases are associated with high incidence, mortality, and disability rates, posing a serious threat to public health. Venous thromboembolism (VTE), in particular, often presents insidiously, and dislodged thrombi can lead to pulmonary embolism—earning it the reputation of a “silent killer.”

At the recent EBMT 2026 Annual Meeting, Prof. Ane Altuna Mongelos from Hospital Clínic de Barcelona and IDIBAPS delivered a presentation titled "CD19/CD84 IF-BETTER dual CAR T cells demonstrate superior control of CD19-low B-ALL than single CAR19." The report explored novel pathways to overcome antigen escape in B-cell acute lymphoblastic leukemia (B-ALL) through a dual-targeting strategy.

As the landscape of hematopoietic stem cell transplantation (HSCT) continues to evolve, umbilical cord blood transplantation (CBT) maintains a critical position in the treatment of hematologic malignancies due to its unique immunological advantages. However, delayed engraftment and high non-relapse mortality (NRM) were once significant bottlenecks limiting its clinical utility. At a recent academic symposium, Professor Annalisa Ruggeri—Chair of the Cell Therapy & Immunobiology Working Party (CTIWP) of the European Society for Blood and Marrow Transplantation (EBMT) and Scientific Chair of Eurocord—delivered a profound presentation on "Regenerative Cord Blood Transplantation." Professor Ruggeri provided an in-depth analysis of the latest advancements, ranging from the optimization of donor selection and conditioning regimens to breakthrough ex vivo expansion technologies such as UM171. Her insights highlighted how technical innovations are overcoming traditional limitations of CBT to deliver superior survival outcomes for high-risk patients.

Severe Aplastic Anemia (SAA), as a highly heterogeneous bone marrow failure (BMF) disorder, continues to present a clinical challenge regarding the optimal choice between immunosuppressive therapy (IST) and hematopoietic stem cell transplantation (HSCT). During the recent European Society for Blood and Marrow Transplantation (EBMT) meeting, Professor Antonio Risitano provided a comprehensive overview of the Severe Aplastic Anemia Working Party (SAAWP) core activities, landmark clinical trials, and biological discoveries. This review deconstructs the key highlights of his presentation to provide clinicians with a cutting-edge international reference for evidence-based medicine.

The advent of Chimeric Antigen Receptor T-cell (CAR-T) therapy has fundamentally transformed the treatment landscape for relapsed/refractory (R/R) hematologic malignancies. However, as clinical adoption expands and follow-up durations extend, the management of treatment-related toxicities—specifically Non-Relapse Mortality (NRM)—has emerged as a critical bottleneck for long-term patient survival. At the 2026 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Dr. Charlotte Graham from London, representing the EBMT Transplant Complications Working Party (TCWP), presented a large-scale real-world study based on the EBMT registry. This analysis of nearly 7,000 CAR-T recipients provides high-granularity insights into NRM risk profiles and clinical intervention strategies.

llogeneic hematopoietic cell transplantation (allo-HCT) remains the only potentially curative intervention for Myelodysplastic Syndromes/Myeloproliferative Neoplasm (MDS/MPN) overlap syndromes. However, due to the high heterogeneity and low incidence of these disorders, the clinical field has long lacked unified criteria for evaluating post-transplant remission and relapse. At the recent European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting, Professor Donal McLornan, Co-Chair of the EBMT Scientific Council and Chair of the Chronic Malignancies Working Party (CMWP), formally presented expert recommendations on the definition of post-transplant remission and the optimization of outcomes on behalf of the Practice Harmonisation and Guidelines Committee. This summary provides a deep dive into the core content of this consensus to guide clinical practice and research.

During the recent workshop "Focus on Allogeneic HSCT in Myelodysplastic Syndromes," Professor Fabio Ciceri (IRCCS San Raffaele Scientific Institute / Vita-Salute San Raffaele University), Chair of the EBMT Scientific Council and the Acute Leukemia Working Party (ALWP), provided a comprehensive overview of "Contemporary Approaches to VEXAS." He systematically detailed the genetic foundations, clinical progression, and multidimensional therapeutic landscape of this complex disease.

At the recent Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Professor Florent Malard from Sorbonne Université, lead of the Microbiome Research Project within the EBMT Cellular Therapy & Immunobiology Working Party, presented the final results of the ARES Phase III clinical trial. The presentation focused on the efficacy and safety of MAAT013, a novel microbiome-based therapeutic, for patients with ruxolitinib-refractory acute graft-versus-host disease with gastrointestinal involvement (GI-aGVHD).

During the EBMT Annual Meeting, Dr. Francesca Ferrua from the IRCCS San Raffaele Scientific Institute presented an integrated analysis of the lentiviral hematopoietic stem and progenitor cell (HSPC) gene therapy, etuvetidigene autotemcel (ototemcel), for the treatment of Wiskott-Aldrich Syndrome (WAS). The report highlighted remarkable efficacy and safety outcomes with a follow-up period extending up to 13 years.

At the EBMT 2026 Annual Meeting, Professor Franco Locatelli from Bambino Gesù Children’s Hospital presented long-term follow-up data for exagamglogene autotemcel (exa-cel), a CRISPR/Cas9-based gene-editing therapy. The study included patients with transfusion-dependent thalassemia (TDT) and sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs). With a median follow-up of over three years and some patients reaching over six years, the results provide robust evidence for the long-term efficacy and safety of gene editing in hereditary blood disorders.